Skip to main content
  •   

    Mechanisms of Anti-VEGF and Prospects for Future ROP Treatments

    By Mary Elizabeth Hartnett, MD, FACS
    AAO 2015
    Pediatric Ophth/Strabismus, Vitreoretinal Diseases

    In this presentation from Pediatric Ophthalmology Subspecialty Day at AAO 2015, Mary Elizabeth Hartnett, MD, discusses why anti-VEGF treatment should be considered in severe retinopathy of prematurity and the dilemma of anti-VEGF treatments in preterm infants.